DAL-302
- Study HIC#:2000039690
- Last Updated:11/26/2025
The dal-GenE-2 clinical research study is testing an investigational medication to treat Acute Coronary Syndrome (ACS) in those who have the target gene variant. The DAL-302 study evaluates the effect of dalcetrapib (Study drug) on the risk of having a major cardiovascular event, including death, heart attack, and stroke.
- Age45 years and older
- GenderBoth
Contact Us
For more information about this study, including how to volunteer, contact:
David Kingsbury, BSN RN
- Phone Number: 1-203-737-1584
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.
Trial Purpose and Description
This is a placebo-controlled, randomized, double-blind, parallel group, phase 3 multicenter study in North America in subjects recently hospitalized for ACS and with the appropriate genetic profile. This study has been designed to provide confirmatory evidence for a reduction in fatal and non-fatal MI as observed in the dal-301 study. Subjects will provide informed consent before any study-specific procedures are performed. A separate informed consent will be allowed for an initial pre-screening genetic testing. Subjects meeting the AA genotype will then consent to the full study and confirmatory genetic testing as required. Subject enrollment may begin in the hospital and will continue following release from the hospital or may begin following release from hospital.
Eligibility Criteria
You are invited to participate in the DAL-302 study if you have recently been hospitalized for ACS. If you participate, you will be screened to see if you have the target gene variant (a difference in a gene that all humans share) and therefore qualify for the study.
